Clinical Trial Update: Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). [Phase 2, Phase 3]

View source ↗

Summary

This entry reports ongoing recruitment for the Phase 2/3 OzoParQT trial (NCT06706544) evaluating gut microbiome profiles in patients with chemotherapy-induced p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Snippet

Sponsor: Bernardino Clavo, MD, PhD | Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2, Phase 3 | Status: RECRUITING